Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.58 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.58 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.58 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7048382 | 0.80 | AGTR1 (0.58) | AGTR1ABCC3ABCC2AGTR2 | |
| SCHEMBL5498758 | 0.78 | AGTR1 (0.55) | AGTR1ABCC3ABCC2AGTR2 | |
| SCHEMBL6060889 | 0.77 | AGTR1 (0.68) | AGTR1ABCC3ABCC2AGTR2 | |
| SCHEMBL7448069 | 0.77 | AGTR1 (0.54) | AGTR1ABCC3ABCC2AGTR2 | |
| SCHEMBL8954159 | 0.74 | AGTR1 (0.61) | AGTR1ABCC3ABCC2AGTR2 | |
| SCHEMBL6855656 | 0.74 | AGTR1 (0.87) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL156290 | 0.73 | AGTR1 (1.00) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL1815060 | 0.73 | AGTR1 (1.00) | AGTR1ABCC3ABCC2 | |
| SCHEMBL9122343 | 0.73 | AGTR1 (0.81) | AGTR1ABCC3ABCC2 | |
| SCHEMBL9122330 | 0.73 | AGTR1 (0.81) | AGTR1ABCC3ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080014263-A1 | Amorphous eprosartan mesylate and process for the preparation thereof | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2008-01-17 | — | — | US | disclosed |
| US-20060286105-A1 | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency | LEDBETTER STEVEN | 2006-12-21 | — | — | US | disclosed |
| US-6387894-B1 | MIXTURE OF CORTICOTROPIN RELEASING FACTOR ANTAGINIST AND RENIN-ANGIOTENSIN SYSTEM INHIBITOR; THERAPY FOR CONGESTIVE HEART FAILURE, HYPOTENSIVE AGENTS | PFIZER INC. | 2002-05-14 | — | — | US | disclosed |
| EP-1059100-A2 | Combinations of CRF antagonists and renin-angiotensin system inhibitors | Pfizer Products Inc. (US) | 2000-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080014263-A1 | Amorphous eprosartan mesylate and process for the preparation thereof | REN, AGT, PTGER1 | AGTR1 4/4885ABCC3 3155/4885ABCC2 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.